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Abstract 
This theme issue presents current achievements in the development of radioactive agents, 
pre-clinical and clinical molecular imaging, and radiotherapy in the context of theranostics in 
the field of oncology. 
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Nuclear medicine is an expanding field for the 
diagnostics and therapy on a molecular level. Current 
nuclear  medicine  diagnostic  techniques  include 
non-invasive  Positron  Emission  Tomography  (PET) 
and Single Photon Emission Computed Tomography 
(SPECT) utilizing, respectively, positron and gamma 
emitting radionuclides for the generation of the sig-
nal.  Both  external  and  internal  radiotherapy  can  be 
directed by diagnostic PET and SPECT, and diagnos-
tic  imaging  and  radiotherapy  are  merging  into 
theranostics resulting in more personalized medicine. 
For example, the individualized diagnosis is becom-
ing a standard in the selection of patients for peptide 
receptor  radionuclide  therapy  wherein  the 
pre-therapeutic  imaging  and  the  radiotherapy  are 
conducted  with  the  same  vector  molecule  by  ex-
changing the imaging and therapeutic radionuclides. 
The  high  value  of  imaging  diagnostics  in  assisting 
cancer  therapy  in  terms  of  early  detection,  staging, 
therapy selection and planning as well as follow-up is 
recognized.  
Development  of  molecular  imaging  and  radio-
therapeutical agents is a complex process  including 
identification of the biological target, respective lead 
compound,  synthesis  of  the  radioactive  agent,  its 
chemical  characterization,  pre-clinical,  and  clinical 
evaluation. Nevertheless, the number of new agents 
for  targeted  imaging  of  specific  protein  expression 
products  (receptors,  enzymes,  and  antigens), 
pre-targeted imaging using small effector or hapten 
molecules  as  well  as  non-targeted  imaging  of  pul-
monary and myocardial perfusion and ventilation is 
increasing  continuously.  Imaging  of  inflammation, 
infection  as  well  as  general  downstream  biologic 
properties such as proliferation, hypoxia, glycolysis, 
and angiogenesis has also been investigated. The in-
troduction  of  new  radiopharmaceuticals  and  their 
accessibility  are  important  factors  determining  the 
expansion of clinical nuclear medicine for early dis-
ease detection and personalized medicine with higher 
therapeutic  efficiency.  This  issue  is  focused  on  the 
targeted and pre-targeted imaging and radiotherapy 
in oncology.  
The role of molecular imaging in the individu-
alized  patient  management  is  hard  to  overestimate 
and it is reflected in the increasing number of specifi-
cally acting imaging agents entering clinical nuclear 
medicine as well as expansion of diverse applications 
Ivyspring  
International Publisher   Theranostics 2012, 2(5) 
 
http://www.thno.org 
425 
of established [18F]flurodeoxyglucose. The review by 
Sörensen  [1]  is  dedicated  to  the  exploration  of  the 
contribution of clinical PET to the improved and per-
sonalized treatment of patients. Diversity of clinical 
PET imaging agents as well as technical and regula-
tory  aspects  are  thoroughly  discussed.  The  review 
provides valuable and comprehensive description of 
considerable  number  of  clinically  relevant  imaging 
agents. 
Molecular  imaging  and  therapy  has  been  inte-
grated  and  most  thoroughly  studied  for  the  man-
agement  of  patients  affected  by  neuroendocrine  tu-
mors  (NETs)  targeting  somatostatin  receptors 
(SSTRs). Therefore, several papers in this issue cover 
various  aspects  of  this  topic.  Two  Centers  of  excel-
lence  recognized  by  European  Neuroendocrine  Tu-
mor  Society,  Zentralklink  Bad  Berka,  Germany  and 
Uppsala University Hospital, Sweden share with us 
their  valuable  experience  in  personalized  medicine 
closely  combining  diagnostic  imaging  and  therapy. 
Baum et al. [2] provide a comprehensive introduction 
of  Theranostics  concept  and  report  on  pioneer  and 
diverse  applications  of  various  imaging  and  thera-
peutic agents in oncology. Öberg [3] reviews various 
imaging and radiotherapeutic agents as well as tar-
gets that can be utilized for the diagnosis and treat-
ment of NETs in the context of personalized medicine. 
Specific example of an outstanding case patient study 
is presented by Garske et al. [4]. The importance of 
177Lu  radionuclide  (in  the  form  of 
177Lu-DOTA-octreotate) for the treatment of patients 
with  highly  proliferating  large  NETs  is  considered 
and highly appreciated. This report also discusses the 
crucial role of imaging and dosimetry in the selection, 
planning, and response monitoring of the treatment. 
The clinical study including 112 patients conducted 
by Delpassand et al. [5] gives an updated perspective 
on the value of 111In radionuclide for the therapeutical 
applications.  The results demonstrate that the high 
dose 111In-Pentetreotide is a safe and effective therapy 
means for patients with disseminated NETs.  
The pioneer studies of SSTRs triggered an accel-
erated  development  of  other  small  peptide  based 
agents targeted to the respective receptors. Fani et al. 
[6]  review  the  current  status  of  somatostatin, 
bombesin,  vasoactive  intestinal  peptide,  gastrin, 
neurotensin, exendin and RGD based analogues de-
veloped for PET and SPECT imaging as well as for the 
radiotherapy  applications  in  oncology.  Imaging 
agents  for  monitoring  general  downstream  biologic 
property such as angiogenesis are reviewed by Backer 
et  al.  [7]  with  focus  on  integrins  and  receptors  for 
vascular endothelial growth factor (VEGF). The key 
application  of  the  respective  radiolabeled  imaging 
ligands  is  monitoring  response  to  anti-angiogenic 
therapy and providing image-guided therapy. 
Another  class  of  specific  protein  expression 
products is enzymes that can be visualized by radio-
labeled  enzyme  inhibitors.  Sundin  [8]  reviews  the 
imaging  agent  arsenal  used  in  the  management  of 
adrenocortical  cancer  with  the  focus  on 
11C-metomidate that binds with high specificity and 
affinity to 11-β-hydroxylase providing the only means 
for the differentiation of benign and malignant adre-
nocortical  tumors  from  those  of  non-adrenocortical 
origin.  This  particular  example  stresses  the  im-
portance of the development of agents specific to tu-
mor characteristics.  
The  current  status  of  the  pre-targeted  imaging 
and  therapy  using  combination  of  a  bispecific  anti-
body and radiolabeled hapten molecule is thoroughly 
reviewed by Goldenberg et al. [9]. The pre-targeting 
concept provides a means to overcome the drawbacks 
related  to  slow  pharmacokinetics  and  prolonged 
blood  circulation  of  labeled  antibodies  resulting  in 
high  radiation  dose  to  the  healthy  tissue  and  poor 
contrast  image.  A  number  of  bispecific  antibodies 
targeting various tumor types have been developed 
and some entered clinical trials.  
In summary,  this theme issue presents current 
achievements  in  the  development  of  radioactive 
agents,  pre-clinical  and  clinical  molecular  imaging 
and radiotherapy in the context of theranostics in the 
field of oncology. The significance of the targeted and 
pre-targeted imaging using PET and SPECT for the 
individualized treatment management and monitor-
ing therapy response is discussed by the authors. The 
content of the issue reflects the worldwide apprecia-
tion of theranostics and its accelerated implementa-
tion  in  nuclear  medicine  with  the  ultimate  aim  for 
personalized medicine. 
The  authors  are  immensely  appreciated  for 
sharing  their  valuable  experience,  knowledge,  and 
perception and contributing to the expansion of clin-
ical nuclear medicine and theranostics. 
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